#ACR21 L17: Heterologous vs Homologous Booster vax ▶️RTX non-responders to mRNA: Randomized to mRNA 3rd dose vs AZ vax ⭐️Majority of pts develop immune response (humoral and/or cellular) after 3rd dose, no statistical diff b/w groups @Rheumnow https://t.co/cuM9LcEr4u https://t.co/cmNBNSIoOl

• https://bit.ly/3mUsMUp

What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVaccination. With 3rd vaccine dose up to 94% can have immune response! Pts need their 3rd vaccination @RheumNow #ACR21 #ACRBest abstL17 https://t.co/0GHOuoqPKQ

👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,⬆️hosp stay,⬆️severity, persistent viremia,⬆️deaths) 👉study adding booster (AZ or mRNA) overcomes this, enhancing humoral and cellular response #ACR21 @rheumnow Abst#L17 https://t.co/yuX1TT6ZBF

Very interesting talk Abst L16 Singh & colleagues found that patients with rheumatic diseases are at increased risk for breakthrough infxn - Recent drug exposure and certain medication type can influence outcomes - Findings support need for 3rd dose in RD pts #ACR21 @RheumNow https://t.co/vU6ZNIEWbc

USA EMR (N3C) Data on 577,335 Rheum Pts w/18,164 #COVID19 breakthrough infx (BTI) 👉91% vax'd 👉3.1% w/BTI 👉86% were vax'd May 2021 or earlier 👉More BTI w/Pfizer 👉BTI higher in inflamm myositis, RA 👉Drugs assc w/BTI: biologics, mult DMARDs #ACR21 @rheumnow Abst#L16 #ACRbest https://t.co/Eu77vAAk3N

#ACR21 L16 - Breakthrough #COVID19 in rheum pts ⭐️Breakthrough ifn ~4%, compared to 3% wo rheum disease. Statistically signif ⬆️ risk in RA, gout, polymyositis, vasculitis, multiple rheum disease ⭐️bDMARD, multiple AIRD risks @Rheumnow https://t.co/cuM9LcEr4u https://t.co/Los2n7BoIn

• https://bit.ly/3mUsMUp

Great case where the #COVIDvaccine was blamed, but he had a diet of doughnuts, steak&cheese sandwiches w/snack cakes, and popsicles. #ThievesMarket #ACR21 @rheumnow https://t.co/J78Nw5NhKs

Abst1625 #ACR21 @RheumNow study of kids w/covid induced MIS-C: 91% w/shock & GI ax, conjunctivitis & mucocutaneous involvement. ⬆️CRP,D-Dimer, Troponin, &BNP. On ECHO, 36% had myocardial dysfunction &27% coronary artery abnormalities. 64% required ICU admiss. Rx IVIG& steroids

#SARSCoV2 infections in vaccinated pts w/ #rheumaticdisease @rheum_covid @rheum_cat 👉🏼Most pts with breakthrough infections were on anti-metabolites or B-cell depleting therapies 👉🏼Encourage patients to get their #BoosterShot! Abs#L04 #ACR21 @RheumNow https://t.co/TAB4zrjPN1 https://t.co/z0gpsxN3xc

• SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Resu…

#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts: ❌No ⬆️ in disease activity scores post-vaccination ❌No serious adverse event ▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls ⭐️RTX and MMF ⬇️ responses @Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW

• https://bit.ly/3kkT94g

#ACR21 Ab#L03: B cell depletors and #COVID19 vax: ⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL ▶️ Timing of vax around B cell return can improve response @Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O

• https://bit.ly/3qjnNij

Breakthrough COVID-19 in rheum pts: great data @rheum_covid B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others Booster (& booster booster) vaccine doses + other mitigation badly needed! @rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi

#ACR21 L04 @rheumcat on #COVID19 in vaxed pts ▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts ⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%). @RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb

• https://bit.ly/306DwGa

#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI

• Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronav…

#ACR21 Abs#1536 #Vaccine uptake in people with #RheumaticDisease 👉🏼High uptake of vaccines in ~240 pts @BrighamWomens 👉🏼84% pts wanted the #COVID19 vaccine 👉🏼Physician recommendation was key determinant of uptake @RheumNow https://t.co/us0i5CW5Mi https://t.co/aLZmOPWFR3

• Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Amo…